Research and Markets: Atrial Fibrillation - Pipeline Review, H1 2014

DUBLIN--()--Research and Markets ( has announced the addition of the "Atrial Fibrillation - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

  • ARCA biopharma, Inc.
  • Armetheon, Inc.
  • Cardiome Pharma Corp
  • Daiichi Sankyo Company, Limited
  • Gilead Sciences, Inc.
  • HUYA Bioscience International, LLC
  • Isis Pharmaceuticals, Inc.
  • Laboratoires Pierre Fabre SA
  • Milestone Pharmaceuticals, Inc.
  • Nissan Chemical Industries, Ltd.
  • Nyken BV
  • Otsuka Holdings Co., Ltd.
  • Serodus ASA
  • Xention Limited

Drug Profiles:

  • edoxaban tosylate
  • tecarfarin
  • vernakalant hydrochloride
  • colchicine
  • bucindolol hydrochloride
  • vernakalant hydrochloride
  • budiodarone
  • ranolazine ER
  • XEN-D0103
  • HBI-3000
  • (ranolazine + dronedarone)
  • vanoxerine
  • F-373280
  • onabotulinumtoxinA
  • XEN-D0101
  • OPC-108459
  • IKACh
  • XEN-D0104
  • HBI-3000
  • MSP-2017
  • SER-102
  • XEN-R0702
  • GsMTx-4
  • NIP-151
  • SER-120
  • budiodarone
  • Drug For Atrial Fibrillation
  • Adenosine A1 Agonist for Atrial Fibrillation
  • Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation

For more information visit


Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular


Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular